Vitrolife AB (OSTO:VITR) ROCE %: 5.63% (As of Mar. 2026)


OSTO:VITR Vitrolife AB OSTO:VITR
79 GF Score
Price kr89.65
GF Value kr162.15
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Vitrolife AB ROCE %?

Vitrolife AB OSTO:VITR +0.11% 79 ROCE % is 5.63% as of Mar. 2026. GuruFocus rates OSTO:VITR with a GF Score™ of 79/100 and a GF Value™ of kr162.15 (Possible Value Trap). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Vitrolife AB's annualized ROCE % for the quarter that ended in Mar. 2026 was 5.63%.

Vitrolife AB  (OSTO:VITR) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Vitrolife AB ROCE % Related Terms

Vitrolife AB ROCE % Historical Data

* Premium members only.

The historical data trend for Vitrolife AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vitrolife AB ROCE % Chart

Vitrolife AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.56 3.03 -20.27 4.72 -35.35

Vitrolife AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.66 3.40 3.54 -157.00 5.63
OSTO:VITR
79GF Score
Vitrolife AB OSTO:VITR
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vitrolife AB ROCE % Calculation

Vitrolife AB's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-4817/( ( (17446 - 705) + (11124 - 615) )/ 2 )
=-4817/( (16741+10509)/ 2 )
=-4817/13625
=-35.35 %

Vitrolife AB's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=596/( ( (11124 - 615) + (11242 - 592) )/ 2 )
=596/( ( 10509 + 10650 )/ 2 )
=596/10579.5
=5.63 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 5.63% mean?
Vitrolife AB (OSTO:VITR) has a ROCE % of 5.63% as of Mar. 2026.
Is Vitrolife AB's ROCE % too high?
Vitrolife AB's current ROCE % is 5.63%. The Medical Devices & Instruments industry median ROCE % is 2.23. Vitrolife AB's value of 5.63% is 152.5% above this industry median. Overall, Vitrolife AB has a GF Score™ of 79/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vitrolife AB's ROCE % compare to ABT and SYK?
Vitrolife AB's ROCE % of 5.63% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. Vitrolife AB's value of 5.63% is 152.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vitrolife AB's current ROCE % of 5.63% is 152.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitrolife AB's current ROCE % is 5.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrolife AB stock overvalued right now?
Based on GuruFocus' analysis, Vitrolife AB (OSTO:VITR) is currently considered Possible Value Trap. The stock's GF Value™ is kr162.15, compared to a current price of kr89.65 — trading 44.7% below its estimated fair value. The current ROCE % is 5.63% and 152.5% above the Medical Devices & Instruments industry median of 2.23. Vitrolife AB's overall GF Score™ is 79/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Vitrolife AB (OSTO:VITR), the current ROCE % is 5.63% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vitrolife AB (OSTO:VITR) Overvalued in 2026?

Based on GuruFocus' analysis, Vitrolife AB stock appears to be undervalued. The current stock price of kr89.65 is trading 44.7% below its estimated GF Value™ of kr162.15. GuruFocus considers Vitrolife AB to be Possible Value Trap.

Key valuation signals for OSTO:VITR:

  • ROCE %: 5.63%
  • GF Value™: kr162.15 vs. price of kr89.65 (44.7% below fair value)
  • GF Score™: 79/100 with 6 warning signs
  • Industry Position: 152.5% above the Medical Devices & Instruments median

No single metric tells the full story. See the OSTO:VITR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vitrolife AB Business Description

Address Box 9080, Gothenburg, SWE, 400 92
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The company has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.
79GF Score

Get the complete analysis for OSTO:VITR

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr89.65
Price
kr162.15
GF Value